NEWSROOM

Healthcare

PRISM Oil & Gas: S&P Sets Fresh YTD High; Falling Gasoline Prices Play Key Role in Cooling Inflation

PRISM Oil & Gas: S&P Sets Fresh YTD High; Falling Gasoline Prices Play Key Role in Cooling Inflation

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - US equities closed mostly higher on Tuesday as the S&P set a fresh year-to-date high, finishing the day at its highest level since January 2022, just 3.2% below its all-time high. Energy stocks underperformed while gasoline prices were down (6%) for the month, playing a key role in cooling inflation numbers for November. The S&P 500 Energy Index was down (1.35%) versus the S&P 500 which rose +0.14%. The XLE settled down (1.39%), the XOP fell...

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - ReShape Lifesciences (Nasdaq: RSLS) has been granted FDA approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX. The company’s share price surged 100% in trading on Wednesday morning. https://prismmarketview.com/companies/reshape-lifesciences-inc/ Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, said, “PMA supplement approval for our next generation Lap-Band® 2.0 FLEX is a...

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - Quoin Pharmaceuticals (Nasdaq: QNRX) has received U.S. Food and Drug Administration (FDA) clearance to implement several protocol amendments to its two ongoing clinical trials for QRX003, which is a potential treatment for Netherton Syndrome, a rare genetic skin disease for which there is no cure and no approved treatments. These protocol amendments are being implemented with a view to generating an even more robust data set and potentially more...

BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors

Dec 13, 2023

POMPANO BEACH, FLORIDA, December 13, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces the appointment of Mr. Thomas J. Dugan to the position of Chairman of the Board. Mr. Dugan brings a wealth of experience to BioStem, with proven, hands-on expertise as a senior executive who has transformed businesses, established new...

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Agreement to Reload Lovelace Medical Center with New Cobalt Sources and Software Upgrade

Dec 13, 2023

Installation expected to be Completed in Mid-2024 SAN FRANCISCO, December 13, 2023 - GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE American: AMS), a leading provider of creative financial and turnkey technology solutions for advanced radiosurgery and radiation oncology services, announced today that it has entered into an agreement with Lovelace Medical Center (LMC), Albuquerque, NM, to reload its Gamma Knife Icon with new Cobalt Sources, as well as install...

MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

Dec 11, 2023

NEW YORK, NY, December 11, 2023 - The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA). The company plans to launch the trial in the first quarter of 2024. Chris Chapman, M.D., president, director, and chief medical officer of MyMD Pharmaceuticals, said, “With the FDA’s recent clearance of our IND in RA, we are moving forward with plans to...

PRISM MediaWire – Weekly Press Resume – Dec. 04 to Dec. 08, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 04 to Dec. 08, 2023

Dec 8, 2023

New York, December 08 , 2023 PRISM MediaWire - Weekly Press Resume Dec 04 to Dec. 08, 2023 Xcyte Digital Produces Second Metaverse Spectrum Business Conference and Launches Inaugural Pitch Fest https://prismmediawire.com/xcyte-digital-produces-second-metaverse-spectrum-business-conference-and-launches-inaugural-pitch-fest/ Peer To Peer Network Announces It Has Hired A PR Firm. Set To Start Major Public Relations Operation Starting In 2024...

PRISM MarketView Biotech Index Top Mover Spotlight: Kamada (KMDA)

Dec 7, 2023

NEW YORK, NY, December 07, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Kamada Ltd. (Nasdaq: KMDA), a commercial-stage global biopharmaceutical company with a portfolio of products for rare and serious conditions and a leader in the specialty plasma-derived field, today announced it has inked its largest commercial agreement to date, set to take effect in January 2024. https://prismmarketview.com/companies/kamada-ltd/...

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Dec 6, 2023

Significant unmet need for regulated product in $2B US testing market Opportunity for expedited pathway for kitted product in development IRVINE, CA, December 06, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte within the recent...

PRISM MARKETVIEW HIGHLIGHTS ALTIMMUNE’S POSITIVE TOPLINE RESULTS IN OBESITY DRUG TRIAL

Dec 5, 2023

NEW YORK, NY, December 05, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, highlights Altimmune, Inc. (Nasdaq: ALT) which has reported positive topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. https://prismmarketview.com/companies/altimmune-inc/ The company’s study enrolled 391 subjects with obesity and at least one comorbidity. Over 50% of subjects achieved at least 15% weight loss and over 30% of subjects achieved at...

PRISM MediaWire – Weekly Press Resume – Nov. 27 to Dec. 01, 2023

PRISM MediaWire – Weekly Press Resume – Nov. 27 to Dec. 01, 2023

Dec 1, 2023

New York, December 1, 2023 PRISM MediaWire - Weekly Press Resume Nov. 27 to Dec. 01, 2023 Two Hands Corporation: Elevating Canada's Micro Merchant Wholesaler Landscape https://prismmediawire.com/two-hands-corporation-elevating-canadas-micro-merchant-wholesaler-landscape/ Metatron’s FanFinder: Enhanced Engagement and Audience Discovery for TikTok and OnlyFans https://prismmediawire.com/metatrons-fanfinder-enhanced-engagement-and-audience-discovery-for-tik-tok-and-onlyfans/ SS Innovations...

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Upgrading at Ecuador Center (GKCE) with State-of-the-Art Gamma Knife ICON

Nov 28, 2023

Upgrade of Gamma Knife® 4C with NEW Elekta ICON for most precise and accurate treatment of Intracranial cancers and other indications SAN FRANCISCO, Nov. 28, 2023 - GK Financing LLC (GKF), a subsidiary of American Shared Hospital Services (NYSE American: AMS), a leading provider of creative financial and turnkey technology solutions for advanced radiosurgery and radiation oncology services, announced today that it has demonstrated its continued commitment in Ecuador by completing the...

PRISM MediaWire – Weekly Press Resume – Nov. 27 to Dec. 01, 2023

PRISM MediaWire – Weekly Press Resume – Nov. 20 to Nov. 24, 2023

Nov 24, 2023

New York, November 24, 2023 PRISM MediaWire - Weekly Press Resume Nov. 20 to Nov. 24, 2023 Dashang Media Unveils Strategic Initiatives for 2023 and Beyond https://prismmediawire.com/dashang-media-unveils-strategic-initiatives-for-2023-and-beyond/ Metatron Captures Spotlight in AI App Arena as ChatGPTplus Pauses Sign-Ups https://prismmediawire.com/metatron-captures-spotlight-in-ai-app-arena-as-chatgptplus-pauses-sign-ups/ EASY ENERGY SYSTEMS TO EXHIBIT AT ORGANIC GROWERS SUMMIT IN MONTEREY, CA...

PRISM MediaWire – Weekly Press Resume – Nov. 13 to Nov. 17, 2023

PRISM MediaWire – Weekly Press Resume – Nov. 13 to Nov. 17, 2023

Nov 17, 2023

New York, Nov. 17, 2023 PRISM MediaWire - Weekly Press Resume Nov. 13 to Nov. 17, 2023 Ethical Web AI Launches AI Seek 4.0 with Almost Real-Time Data https://prismmediawire.com/ethical-web-ai-launches-ai-seek-4-0-with-almost-real-time-data/ AmpliTech to Host Quarterly Investor Call to Review Q3 2023 Earnings on Tuesday November 14, 4:30 PM ET; Dial-in # 1-833-630-0019 or 1-412-317-1807...

PRISM MarketView Spotlights Significant Market Opportunities in Global Health with Launch of Emerging Public Health Index

Nov 14, 2023

NEW YORK, NY, November 14, 2023 - PRISM MarketView, a leader within the financial markets and news community, has debuted its PRISM Emerging Public Health Index. https://prismmarketview.com/index/public-health/ The Public Health segment highlights the most critical health crises impacting the world’s population today - including dementia, diabetes, stroke, hypertension and heart disease - as identified by the World Health Organization (WHO). The PRISM Public Health index focuses on the...

BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results

BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results

Nov 14, 2023

Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT POMPANO BEACH, FLORIDA, November 13, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2023. Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “2023 has been a remarkable year of growth...

PRISM MediaWire – Weekly Press Resume – Nov. 13 to Nov. 17, 2023

PRISM MediaWire – Weekly Press Resume – Nov. 6 to Nov. 10, 2023

Nov 10, 2023

New York, New York, Nov. 10, 2023 PRISM MediaWire - Weekly Press Resume Nov. 6 to Nov. 10, 2023 Two Hands Corporation Launches Sports Illustrated Line Protein Bars in Canada https://prismmediawire.com/two-hands-corporation-launches-sports-illustrated-line-protein-bars-in-canada/ BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023...

Oncocyte Reports Third Quarter 2023 Financial Results

Nov 9, 2023

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is...

BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

Nov 8, 2023

POMPANO BEACH, FLORIDA, November 8, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279 for VENDAJE AC® pursuant to its application for Healthcare Common Procedure Coding System (HCPCS) “Q” codes. The HCPCS code assigned for VENDAJE...

BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Nov 6, 2023

POMPANO BEACH, FLORIDA, November 6, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its third quarter 2023 financial results pre-market on Tuesday, November 14, 2023. BioStem will host a conference call and webcast at 10:30am ET on Tuesday, November 14, 2023. The call will include a discussion of...

BioStem Technologies Closes Oversubscribed $2M Private Placement

BioStem Technologies Closes Oversubscribed $2M Private Placement

Nov 3, 2023

POMPANO BEACH, FLORIDA, November 3, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units (each, a “Unit”) at a price of $1.50 per Unit for gross proceeds of $2 million. Each Unit consists of one...

Oncocyte to Announce Third Quarter 2023 Financial Results

Nov 3, 2023

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day,...

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

Oct 24, 2023

NEW YORK, NY, October 24, 2023 - The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash...

BioStem Technologies Closes Oversubscribed $2M Private Placement

BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study

Oct 24, 2023

Study to support differentiated efficacy of Vendaje® structural tissue allograft POMPANO BEACH, FLORIDA, October 24, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that the first site is now fully opened for its clinical trial, evaluating the Vendaje® tissue allograft in the treatment of diabetic foot ulcers (DFU). Jason...

PRISM MarketView Launches Mental Health Index on World Mental Health Day

Oct 11, 2023

Index Highlights Innovative Companies Addressing the Unseen Challenges of Mental Disorders New York City, October 11, 2023 - In honor of World Mental Health Day, which raises awareness of mental health issues on a global scale, PRISM MarketView has introduced the Prism Emerging Mental Health Index, a proprietary index focused on pioneering stocks offering innovative treatments for mood issues, anxiety, personality disorders and more....

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Sep 18, 2023

Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference. The data was generated from a...

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023

CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 with registered investors during the conference. The Company’s virtual presentation...

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Aug 28, 2023

First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA, August 28, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company’s VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX:...

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte Reports Second Quarter 2023 Financial Results

Aug 10, 2023

Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 10, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights Transplant product launch on pace for Q4 early access. Manufacturing transfer process for 48-target universal assay began in June Expanding clinical utility for VitaGraft Kidney, a recent...

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

ONCOCYTE REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS

Aug 9, 2023

IRVINE, CA, August 9, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company was previously notified by Nasdaq on August 9, 2022 that it was not in compliance with the minimum bid price...